Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus
Completed · Phase 2 · NCT03920267
Conditions: Systemic Lupus Erythematosus
At a glance
- Research payments reported, 2025
- $166,210
- U.S. investigators named
- 19
- Sites paid
- 18
- Planned or actual enrollment
- 261
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- BMS-986165 (drug)
- Dates
- Started 2019-03-26; completion 2025-03-21
- Results posted
- Yes
The main objective of the trial is to characterize the long-term safety and tolerability of BMS-986165 in subjects with Systemic Lupus Erythematosus (SLE).
From ClinicalTrials.gov, last updated 2026-03-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $166,210 in research payments for this study in 2025 (21 payments).
Products named: Sotyktu
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jose E. Rubio Mosquera, M.D Rheumatology · Birmingham, AL
- George Karpouzas, M.D. Rheumatology · Torrance, CA
- Kwabena Ayesu, MD Internal Medicine · Orlando, FL
- Michael R. Bubb, MD Rheumatology · Gainesville, FL
- Michael D. Kohen, M.D. Allergy & Immunology · Daytona Beach, FL
- Kimberly M. Smith, MD Rheumatology · Tampa, FL
- Theresa A. Lawrence-ford, M.D. Rheumatology · Lawrenceville, GA
- Alireza Nami, M.D. Rheumatology · Charlotte, NC
- Saira Z. Sheikh, M.D. Internal Medicine · Chapel Hill, NC
- David H. Goddard, MD Rheumatology · Brooklyn, NY
- Amit Saxena, MD Rheumatology · New York, NY
- Cristina G. Arriens, MD Rheumatology · Oklahoma City, OK
- James C. Oates, MD Rheumatology · Charleston, SC
- Jacob Aelion, M.D. Specialist · Jackson, TN
- Anurekha B. Chadha, MD Rheumatology · Austin, TX
- David R. Karp, MD Rheumatology · Dallas, TX
- Amber Khan, M.D Internal Medicine · Houston, TX
- Paul K. Pickrell, MD Rheumatology · Austin, TX
- Atul K. Singhal, M.D. FACR Rheumatology · Mesquite, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- NYU Langone Hospitals - Tisch Hospitals Clinical Labs $31,654
- $27,309
- University of Alabama Hospital, AL $20,910
- West Tennessee Research Institute $19,118
- The University of North Carolina at Chapel Hill $8,980
- Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center $8,237
- Millennium Research $6,790
- Omega Research Group Metrowest $6,735
- Joint and Muscle Research Institute $5,504
- Adventhealth Tampa, FL $4,504
- Southwest Rheumatology Research Llc $4,167
- Austin Regional Clinic, PA $3,883
- North Georgia Rheumatology Group $3,658
- University of Texas Southwestern $3,279
- Medical University of South Carolina $3,040
- Tekton Research $3,002
- Accurate Clinical Management, Llc $2,803
- Oklahoma Medical Research Foundation $2,500
- University of Florida Board of Trustees $135
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.